PT-141 Research: What Studies Show About Bremelanotide

PT-141 research focuses on bremelanotide, a synthetic cyclic heptapeptide that acts as a melanocortin receptor agonist, mainly at MC4R, to influence central nervous system pathways involved in sexual desire and arousal. Bremelanotide is FDA-approved in the United States as Vyleesi for premenopausal women with hypoactive sexual desire disorder (HSDD), but PT-141 sold as a research peptide is not approved for human use.

What PT-141 Is and How It Works

PT-141 was derived from Melanotan II, a non-selective melanocortin peptide first explored for skin pigmentation. Bremelanotide binds MC1R, MC3R, MC4R, and MC5R, and its effects on desire are attributed primarily to MC4R activation in the hypothalamus.

PT-141 does not work like a PDE5 inhibitor. It does not act directly on genital blood vessels; instead, its proposed mechanism is central, signaling through melanocortin pathways that help regulate motivation, appetite, and energy balance.

Property	Detail
Compound	Bremelanotide (PT-141)
Peptide class	Cyclic heptapeptide, melanocortin agonist
Primary target	MC4R, with activity at MC1R, MC3R, MC5R
Approved form	1.75 mg subcutaneous autoinjector (Vyleesi)
Plasma half-life	About 2.7 hours
Routes studied	Subcutaneous injection, intranasal spray

What Clinical Trials Show

The RECONNECT 1 and RECONNECT 2 phase 3 trials tested 1.75 mg subcutaneous bremelanotide in premenopausal women with HSDD. Participants dosed as needed before anticipated sexual activity, and the trials reported statistically significant but modest improvements in desire and reductions in distress compared with placebo.

Response was far from universal. Only a minority of participants met the trials' responder definitions, which is why regulators and clinicians describe the benefit as modest rather than dramatic.

PT-141 is not FDA-approved for use in men, and clinical data in men remain limited. Studies in postmenopausal women are also sparse, so results from premenopausal HSDD trials should not be generalized to other groups.

Dosing Used in Published Research

Published human research uses a narrow range of doses, and the route of administration changes both absorption and tolerability.

• Subcutaneous: 1.75 mg, no more than once every 24 hours and no more than eight doses per month in the approved label.
• Intranasal: Older trials used 10 mg and 20 mg sprays; nausea at the higher dose limited further development of that route.
• Timing: Dosing at least 45 minutes before anticipated activity is standard in trial protocols.

Human trials that inform pt-141 dosage for women used a single 1.75 mg subcutaneous dose per occasion. When people ask how long does pt-141 last, pharmacokinetic data point to a plasma half-life of about 2.7 hours, with peak levels around one hour after injection.

Nasal Spray vs Injection

Researchers comparing pt-141 nasal spray vs injection generally look at onset, bioavailability, and tolerability. Intranasal delivery is less invasive but absorbs less predictably, and older nasal trials needed much larger doses to produce measurable effects.

Factor	Nasal spray	Subcutaneous injection
Typical research dose	10-20 mg	1.75 mg
Onset	Roughly 30-60 minutes	Peak plasma around 1 hour
Bioavailability	Lower and more variable	Higher and more consistent
Main tolerability issue	Nausea at higher doses	Injection site reactions
FDA status	Not approved	Approved as Vyleesi

For most published human data, the subcutaneous route is the better-characterized option. Nasal spray formulations remain a research interest rather than an approved delivery method.

Side Effects and Safety Considerations

Bremelanotide's side effect profile is well documented in the phase 3 trials, and tolerability is the main reason some users stop treatment.

• Nausea, reported in roughly 40 percent of trial participants and the most common reason for discontinuation.
• Flushing, headache, vomiting, cough, and dizziness.
• Injection site reactions such as pain, bruising, or irritation.
• Transient increases in blood pressure and heart rate, typically within the first hours after dosing.
• Focal hyperpigmentation of the skin with repeated use.

Bremelanotide is contraindicated in people with uncontrolled high blood pressure or known cardiovascular disease. It may also slow gastric emptying, which can affect how quickly oral medications are absorbed.

Anyone considering PT-141 should discuss cardiovascular history, blood pressure, and current medications with a healthcare professional. PT-141 is not a cure for sexual dysfunction, and self-dosing with unapproved research peptides carries unknown risks.

Sourcing and Quality in PT-141 Research

When researchers ask where to buy pt-141, the honest answer is that no research peptide vendor holds FDA approval for human use. A pt 141 peptide research pharmacy typically operates outside normal pharmaceutical oversight, which puts the burden of quality verification on the buyer.

Reasonable quality checks for any peptide purchase include:

• A third-party certificate of analysis (COA) from an accredited laboratory.
• HPLC purity data and mass spectrometry confirmation of molecular identity.
• Batch-specific testing rather than generic documentation.
• Cold-chain shipping and clear storage instructions.

Purity matters because impurities and incorrect peptide sequences can confound research results and introduce unknown safety risks if the material is ever used outside a laboratory setting.

PT-141 remains an active area of study for central melanocortin signaling and sexual desire, but the gap between approved medical use and unregulated research peptides is wide. Evidence-based decisions belong with a qualified healthcare professional.

COMMON QUESTIONS

Frequently Asked Questions

Is PT-141 FDA-approved?

Yes, but only in one specific form and population. Bremelanotide is FDA-approved as Vyleesi, a 1.75 mg subcutaneous autoinjector, for premenopausal women with hypoactive sexual desire disorder. Research-grade PT-141 sold online is not FDA-approved and is labeled for laboratory use only.

How long does PT-141 take to work?

After subcutaneous injection, peak plasma levels are reached in about one hour, and the half-life is roughly 2.7 hours. Trial protocols instructed participants to dose at least 45 minutes before anticipated sexual activity. Self-reported effects can extend for several hours after a single dose.

What are the most common side effects of PT-141?

Nausea, flushing, headache, and injection site reactions are the most frequently reported side effects in clinical trials. Nausea occurs in roughly 40 percent of users and is the main dose-limiting effect. Transient increases in blood pressure and heart rate have also been observed.